Education
About Us
Working with TipRanks
Follow Us
Allakos (ALLK)
NASDAQ:ALLK
ALLK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.22 - $1.56
Previous CloseN/A
Volume85.32K
Average Volume (3M)N/A
Market Cap
$29.74M
Enterprise Value-$34.78M
Total Cash (Recent Filing)$139.25M
Total Debt (Recent Filing)$40.43M
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Aug 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding48,412,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit17.88
Enterprise Value/Ebitda0.31
Forecast
1Y Price Target
$0.40Price Target Upside21.21% Upside
Rating ConsensusHold
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
EarningsALLK reported a net income for the quarter, reflecting a stable financial position despite challenges.
Financial PositionThe company ended the quarter with a substantial amount of cash and equivalents.
Bears Say
Clinical Trial ResultsAK006 failed to demonstrate therapeutic activity vs. placebo, and that further development of AK006 is being discontinued.
Restructuring CostsA significant portion of the company's cash will be used for restructuring activities and termination of their lead asset's development.
Workforce ReductionThe Allakos workforce is being reduced by approximately 75%.
Allakos News
ALLK FAQ
What was Allakos’s price range in the past 12 months?
Allakos lowest stock price was $0.21 and its highest was $1.55 in the past 12 months.
What is Allakos’s market cap?
Allakos’s market cap is $29.74M.
When is Allakos’s upcoming earnings report date?
Allakos’s upcoming earnings report date is Aug 06, 2025 which is 2 days ago.
How were Allakos’s earnings last quarter?
Currently, no data Available
Is Allakos overvalued?
According to Wall Street analysts Allakos’s price is currently Undervalued.
Does Allakos pay dividends?
Allakos does not currently pay dividends.
What is Allakos’s EPS estimate?
Allakos’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Allakos have?
Allakos has 48,412,000 shares outstanding.
What happened to Allakos’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Allakos?
Currently, no hedge funds are holding shares in ALLK
Allakos Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$0.40 (21.21% Upside)
$0.40 (21.21% Upside)
Blogger Sentiment
Bearish
ALLK Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 8.1%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
-88.87%
Trailing 12-Months
Asset Growth
-66.42%
Trailing 12-Months
Company Description
Allakos
Allakos Inc. is a biotechnology company that focuses on the development of therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company's primary product candidate is lirentelimab (AK002), designed to target specific immune cells implicated in various diseases. Allakos operates within the healthcare sector, specifically in the biopharmaceutical industry, where it seeks to address unmet medical needs through innovative biologic treatments.
Allakos (ALLK) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
ALLK Stock 12 Month Forecast
Average Price Target
$0.40
▲(21.21% Upside)
Ownership Overview
9.07% Insiders
2.09% Mutual Funds
<0.01% Other Institutional Investors
97.91% Public Companies and Individual Investors